"目錄號(hào): HY-15332

Vitamin D Related-

Alfacalcidol-D6是氘化的Alfacalcidol(1-hydroxycholecalciferol; Alpha D3; 1.alpha.-Hydroxyvitamin D3)，是非選擇性的VDR活化劑。

VD/VDR

相關(guān)產(chǎn)品

Calcitriol-Calcipotriol-Maxacalcitol-Ercalcidiol-Alfacalcidol-Calcifediol monohydrate-Paricalcitol-Seocalcitol-Secalciferol-3-O-(2-Aminoethyl)-25-hydroxyvitamin D3-Ercalcitriol-Vitamin D4-Calcitetrol-Calcitriol Impurities A-Cholecalciferol-

生物活性

Description

Alfacalcidol-D6, a deuterated Alfacalcidol (1-hydroxycholecalciferol; Alpha D3; 1.alpha.-Hydroxyvitamin D3), is a non-selective VDR activator medication. IC50 value: Target: VDR activatorAlfacalcidol (1-hydroxycholecalciferol; Alpha D3; 1.alpha.-Hydroxyvitamin D3) improves mechanical bone strength and bone mass; suppresses osteoclastic bone resorption in vivo.

References

[1].Shiraishi et al (2000) Alfacalcidol inhibits bone resorption and stmulates formation in an ovariectomized rat model of osteoporosis: Distinct actions from estrogen. Journal of Bone and Mineral Research. 15 770.

[2].Ringe JD, Schacht E. et al. Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol. Rheumatol Int. 2004 Jul;24(4):189-97.

[3].Ivarsen P, Povlsen JV, Christensen KL.Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: A pilot study.Scand J Urol Nephrol. 2012 Jun 25.

[4].Rianthavorn P,et al. Prevention of bone loss in children receiving long-term glucocorticoids with calcium and alfacalcidol or menatetrenone.J Pediatr Endocrinol Metab. 2012;25(3-4):307-12.

[5].Ringe JD, Farahmand P, Schacht E.Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.Rheumatol Int. 2012 Apr 8.